{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:17Z","timestamp":1787071037199,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of our study was to evaluate the detection rate of prostate cancer by digital rectal examination (DRE) and serum prostate-specific antigen (PSA) levels followed by standard 12-core transrectal ultrasound (TRUS)-guided prostate biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>After screening of patients presenting with lower urinary tract symptoms (LUTS) using DRE and serum PSA level, we enrolled patients for TRUS-guided 12-core prostate biopsy. Indications included PSA level \u22654 ng\/ml and\/or suspicious DRE findings. A retrospective analysis was done to find out the correlation between suspicious rectal examination and various serum PSA levels in detection of cancer prostate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 847 patients were screened for cancer prostate during our study period (May 2012\u2013February 2020). Among them, 823 patients who underwent prostate biopsy were analyzed. Prostate cancer was detected in 330 cases (40.09%). Mean age of patient (years) with and without prostate cancer was 66.25 \u00b1 9.45 and 64.3 \u00b1 8.96 years, respectively. Median value of serum PSA in patients positive for cancer was 33 \u00b1 260 ng\/ml compared to patients without cancer, who had a median value of 9 \u00b1 64 ng\/ml (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value of &lt;0.0001). The detection rate of cancer based on suspicious DRE findings irrespective of PSA was 52.18% (251\/481), compared to 45.46% (311\/684) using a PSA cut-off of \u22654.0 ng\/ml alone. Among 330 patients with positive biopsy, 19 (5.75%) had a PSA level &lt;4 ng\/ml and they were identified based on suspicious DRE alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Suspicious DRE was significantly associated with detection of prostate cancer across all PSA levels. Patients with PSA &lt;4 can harbor prostate malignancy and such cases can be detected by use of DRE in screening of all patients with LUTS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1818_20","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:37:21Z","timestamp":1668645441000},"page":"1646-1650","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Correlation of digital rectal examination and serum prostate-specific antigen levels for detection of prostate cancer"],"prefix":"10.4103","volume":"18","author":[{"given":"Debansu","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20241021","first-page":"679","article-title":"Early diagnosis of prostate cancer in the Western Cape","volume":"91","author":"Heyns","year":"2001","journal-title":"S Afr Med J"},{"key":"R2-32-20241021","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1001\/jama.1984.03350230021025","article-title":"Early detection of prostate cancer by routinescreening","volume":"252","author":"Chodak","year":"1984","journal-title":"JAMA"},{"key":"R3-32-20241021","first-page":"83","article-title":"Relationship of prostate specific antigen and digital rectal examination in prediction of prostate cancer","volume":"16","author":"Timilsina","year":"2020","journal-title":"JCMS"},{"key":"R4-32-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12301-019-0013-2","article-title":"Assessment of the value of the different variants of abnormal digital rectal examination finding in predicting carcinoma of the prostate: A preliminary report of two center study","volume":"26","author":"Irekpita","year":"2020","journal-title":"Afr J Urol"},{"key":"R6-32-20241021","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","article-title":"Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators","volume":"61","author":"Roobol","year":"2012","journal-title":"Eur Urol"},{"key":"R7-32-20241021","doi-asserted-by":"crossref","first-page":"509","DOI":"10.6004\/jnccn.2016.0060","article-title":"NCCN guidelines insights: Prostate cancer early detection, version 2.2016","volume":"14","author":"Carroll","year":"2016","journal-title":"J Natl Comp Cancer Netw"},{"key":"R8-32-20241021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA Guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"R9-32-20241021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-5347(17)38664-0","article-title":"Random systematic versus directed ultrasound guided transrectal core biopsies of theprostate","volume":"142","author":"Hodge","year":"1989","journal-title":"J Urol"},{"key":"R10-32-20241021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0301-5629(00)00352-5","article-title":"History of ultrasound in nephrourology","volume":"27","author":"Watanabe","year":"2001","journal-title":"Ultrasound Med Biol"},{"key":"R11-32-20241021","first-page":"93","article-title":"Prostate biopsy: Current status and limitations","volume":"9","author":"Presti","year":"2007","journal-title":"Rev Urol"},{"key":"R12-32-20241021","first-page":"262","article-title":"Using biopsy to detect prostate cancer","volume":"10","author":"Shariat","year":"2008","journal-title":"Rev Urol"},{"key":"R13-32-20241021","doi-asserted-by":"crossref","first-page":"273S","DOI":"10.1016\/S0197-2456(00)00098-2","article-title":"Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial","volume":"21","author":"Prorok","year":"2000","journal-title":"Control Clin Trials"},{"key":"R14-32-20241021","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.juro.2017.10.021","article-title":"Utility of digital rectal examination (DRE) as an adjunct to prostate specific antigen (PSA) in the detection of clinically significant prostate cancer","volume":"199","author":"Halpern","year":"2018","journal-title":"J Urol"},{"key":"R15-32-20241021","doi-asserted-by":"crossref","first-page":"433e8","DOI":"10.1093\/jnci\/dji065","article-title":"Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: Findings from the initial screening round of a randomized trial","volume":"97","author":"Andriole","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R16-32-20241021","doi-asserted-by":"crossref","first-page":"1320e8","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in arandomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-32-20241021","first-page":"982","article-title":"Complexation of prostate specific antigen (PSA) in serum","volume":"38","author":"Zhou","year":"1992","journal-title":"Clin Chem"},{"key":"R18-32-20241021","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/0277-5379(91)90236-7","article-title":"Prostate-specific antigen: Problems in analysis","volume":"27","author":"Turkes","year":"1991","journal-title":"Eur J Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1818_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:37Z","timestamp":1787067637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1818_20"}},"subtitle":["Retrospective analysis results from a tertiary care urology center"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1818_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}